Apeiron Signs Regional License Agreements with Medison Pharma (Israel) and Gen Ilac ve Saglik Ürünleri (Turkey) for the Commercialization of its Neuroblastoma Therapy

Apeiron today announced the signing of two transactions as part of the worldwide commercialization of APN311, an antibody-based immunotherapy in development for the treatment of children suffering from high-risk neuroblastoma. Press release

January 9, 2014
View the Post

APEIRON Biologics AG Collaborates with Idis Ltd to Initiate Managed Access Program

Apeiron today announced that it has retained the services of Idis Ltd to initiate a Managed Access Program for its product APN311 (ch14.18/CHO), for patients with high-risk neuroblastoma. The program will run in specified countries throughout the world and is expected to be initiated in Q4 2013. Press release

September 25, 2013
View the Post

Positive outcome in clinical study to prevent radiation-induced dermatitis in breast cancer patients

APEIRON Biologics AG today announced that the clinical trial with their liposomal formulation of recombinant superoxide dismutase (project APN201) which started in March 2012 concluded with positive outcomes in all endpoints analyzed. Press release

March 5, 2013
View the Post